Frontiers in Cardiovascular Medicine (Jun 2022)
Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
Abstract
No abstracts available.Keywords